Bio-techne Corp (NASDAQ:TECH)’s Stock Is Buy After Less Market Selling

July 14, 2018 - By James Guidry

Bio-Techne Corporation (NASDAQ:TECH) Logo

Investors sentiment increased to 1.32 in 2018 Q1. Its up 0.34, from 0.98 in 2017Q4. It improved, as 14 investors sold Bio-Techne Corporation shares while 89 reduced holdings. 53 funds opened positions while 83 raised stakes. 35.01 million shares or 1.47% less from 35.53 million shares in 2017Q4 were reported.
Cornerstone Advisors has 0% invested in Bio-Techne Corporation (NASDAQ:TECH). Barclays Plc has 22,235 shares for 0% of their portfolio. Advantus Mngmt Inc has 4,614 shares for 0.02% of their portfolio. Paradigm Asset invested 0% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). Atria Invests Ltd Llc has 0.01% invested in Bio-Techne Corporation (NASDAQ:TECH) for 1,387 shares. Bogle L P De has 0.58% invested in Bio-Techne Corporation (NASDAQ:TECH) for 50,698 shares. 1,650 were accumulated by Aull Monroe Management. Robeco Institutional Asset Mngmt Bv owns 20,324 shares. Envestnet Asset Mngmt Incorporated stated it has 9,616 shares. Kopp Advisors Ltd Liability Com holds 0.31% or 2,000 shares in its portfolio. State Common Retirement Fund reported 399,481 shares. Teachers Retirement Of The State Of Kentucky accumulated 6,808 shares. Two Sigma Securities Ltd Liability holds 0% in Bio-Techne Corporation (NASDAQ:TECH) or 2,694 shares. Granite Inv Prtnrs Limited Liability Company accumulated 0.11% or 11,234 shares. Bamco New York stated it has 1.52 million shares or 1.06% of all its holdings.

Since February 13, 2018, it had 0 insider purchases, and 3 insider sales for $2.13 million activity. Eansor Norman David also sold $164,932 worth of Bio-Techne Corporation (NASDAQ:TECH) on Friday, May 4. Another trade for 8,000 shares valued at $1.28M was made by Kummeth Charles R. on Thursday, June 7.

The stock of Bio-techne Corp (NASDAQ:TECH) registered a decrease of 6.01% in short interest. TECH’s total short interest was 916,100 shares in July as published by FINRA. Its down 6.01% from 974,700 shares, reported previously. With 152,400 shares average volume, it will take short sellers 6 days to cover their TECH’s short positions. The short interest to Bio-techne Corp’s float is 2.45%.

The stock decreased 0.14% or $0.21 during the last trading session, reaching $153.11. About 108,484 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 33.83% since July 14, 2017 and is uptrending. It has outperformed by 21.26% the S&P500.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.75 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 51.73 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 6 analysts covering Bio-Techne Corporation (NASDAQ:TECH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Bio-Techne Corporation has $185 highest and $142.0 lowest target. $161.50’s average target is 5.48% above currents $153.11 stock price. Bio-Techne Corporation had 9 analyst reports since January 18, 2018 according to SRatingsIntel. The rating was downgraded by Deutsche Bank to “Hold” on Wednesday, June 27. As per Thursday, January 18, the company rating was maintained by Robert W. Baird. The company was maintained on Wednesday, February 7 by Craig Hallum. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Deutsche Bank on Thursday, March 1. On Tuesday, February 6 the stock rating was maintained by Robert W. Baird with “Buy”. The firm earned “Buy” rating on Thursday, May 3 by Leerink Swann. As per Thursday, May 3, the company rating was maintained by Deutsche Bank. On Wednesday, February 7 the stock rating was maintained by Stephens with “Hold”.

More recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: which released: “BioTechne to buy Exosome Diagnostics” on June 25, 2018. Also published the news titled: “Bio-Techne (TECH) Announces Antibody Validation Initiative Using CRISPR Gene Editing Technology Across Broad …” on July 10, 2018.‘s news article titled: “Sell tech! Morgan Stanley’s warning to investors” with publication date: July 09, 2018 was also an interesting one.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: